In an early piece of work, EPO 40 000 U biweekly as induction therapy followed by 40 000 U weekly maintenance was demonstrated effective in rapidly correcting anaemia, improving quality of life (QoL) and reducing transfusion requirements in LR‐MDS patients with Hb <10 g/dL. This evidence concerns the gene GSTM1 and myelodysplastic syndrome.